Sagimet Biosciences Inc - Series A — Cash Flow (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Cash from operating activities -23.77 M-42.44 M -44.84 M Cash from investing activities 12.58 M-61.68 M 48 K Cash from financing activities 86.17 M104.82 M — Free cash flow -23.77 M-42.44 M -44.84 M

新闻

Sagimet生物科学股票在痤疮药物安全性数据积极后上涨

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

歌礼制药-B(01672)：同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理

Sagimet Biosciences executive chairman sells $290k in shares

Citizens上调Sagimet Biosciences目标价至35美元

Sagimet Biosciences stock price target raised to $35 by Citizens

丹尼凡斯塔特在中国的第三期痤疮临床试验中达到所有终点

Denifanstat meets all endpoints in phase 3 acne trial in China